• Jing Wang, Shu-Hong Shen, Bin-Fei Hu, and Guan-Ling Wang.
• Ningbo Women and Children's Hospital, Ningbo.
• Medicine (Baltimore). 2021 Jun 25; 100 (25): e26440e26440.

RationaleRelapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL). To the best of our knowledge, this is the first report on the successful use of 2 targeted drugs such as trametinib and dasatinib in a pediatric patient with Ph+ ALL and recurrent pancreatitis.Patient ConcernsA 6-year-old boy with ALL and Philadelphia chromosome (Ph+) who had recurrent asparaginase-associated pancreatitis.DiagnosisThe patient was diagnosed with ALL, based on clinical features, laboratory analyses, bone marrow aspiration evaluation in morphology, immunology, cytogenetics, and molecular.InterventionsThe patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy. However, owing to recurrent asparaginase-associated pancreatitis, the patient has to abandon asparaginase in consolidation. Considering the high risk of relapse, we used trametinib and dasatinib combined with chemotherapy as maintenance chemotherapy.OutcomesAfter 6 months, there were no obvious side effects or residual disease.LessonsWe suggest that the combination of trametinib and dasatinib may represent a viable option to treat patients with potential relapsed/refractory Ph+ ALL.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

48 keywords...

hide…